Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

CymaBay Therapeutics, Inc. (CBAY)

3.3   -0.01 (-0.3%) 11-25 13:00
Open: 3.29 Pre. Close: 3.31
High: 3.37 Low: 3.29
Volume: 62,829 Market Cap: 279(M)

Technical analysis

as of: 2022-11-25 1:55:48 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.28     One year: 4.66
Support: Support1: 3.15    Support2: 2.62
Resistance: Resistance1: 3.67    Resistance2: 3.99
Pivot: 3.39
Moving Average: MA(5): 3.3     MA(20): 3.41
MA(100): 3.53     MA(250): 3.12
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 16.5     %D(3): 16.6
RSI: RSI(14): 45.2
52-week: High: 4.3  Low: 1.66
Average Vol(K): 3-Month: 343 (K)  10-Days: 268 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CBAY ] has closed above bottom band by 32.2%. Bollinger Bands are 25.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.35 - 3.37 3.37 - 3.39
Low: 3.16 - 3.19 3.19 - 3.21
Close: 3.27 - 3.31 3.31 - 3.34

Company Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Headline News

Thu, 24 Nov 2022
Health Service Provider Services Market: Key Vendors, Global Share, Emerging Trends, Segmentation, Reliability & 2030 Forecast Analysis - Digital Journal

Wed, 23 Nov 2022
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) may have lost US$34m in value but insiders who invested last year have seen gains of around US$72k to date - Yahoo Finance UK

Thu, 17 Nov 2022
Oppenheimer Trims CymaBay Therapeutics (NASDAQ:CBAY) Target Price to $10.00 - MarketBeat

Sun, 13 Nov 2022
Notable earnings after Monday's close - Seeking Alpha

Thu, 10 Nov 2022
CymaBay Therapeutics (CBAY) will report earnings on Monday. - Best Stocks

Fri, 04 Nov 2022
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver MeetingĀ® 2022 - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 85 (M)
Shares Float 62 (M)
% Held by Insiders 0.3 (%)
% Held by Institutions 76.2 (%)
Shares Short 1,810 (K)
Shares Short P.Month 1,580 (K)

Stock Financials

EPS -1.33
EPS Est Next Qtl -0.16
EPS Est This Year -0.82
EPS Est Next Year -0.75
Book Value (p.s.) 0.7
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -41.8
Return on Equity (ttm) -143.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.52
Sales Per Share 0
EBITDA (p.s.) -1.11
Qtrly Earnings Growth 0
Operating Cash Flow -80 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -2.5
PEG Ratio 0
Price to Book value 4.64
Price to Sales 0
Price to Cash Flow -3.52

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.